rAAV2.REP1

DRUG2 trials

Sponsors

University of Oxford, STZ eyetrial

Conditions

Choroideremia

Phase 1

Gene Therapy for Blindness Caused by Choroideremia

CompletedNCT01461213

University of OxfordChoroideremia

Start: 2011-10-31End: 2017-10-31Updated: 2017-11-17

Phase 2

THOR - Tübingen Choroideremia Gene Therapy Trial

CompletedNCT02671539

STZ eyetrialChoroideremia

Start: 2016-01-31End: 2018-02-28Updated: 2020-10-27

Related Papers

Choroideremia Gene Therapy

International Ophthalmology Clinics2021-09-2818 citations

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations

Update on Gene Therapy Clinical Trials for Choroideremia and Potential Experimental Therapies.

2021-01-1210 citations

Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia

JAMA Ophthalmology2019-08-2985 citations

CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA

Retina2018-10-1061 citations

The Spectrum of CHM Gene Mutations in Choroideremia and Their Relationship to Clinical Phenotype

Investigative Ophthalmology & Visual Science2016-11-0779 citations

Correlation of Optical Coherence Tomography and Autofluorescence in the Outer Retina and Choroid of Patients With Choroideremia

Investigative Ophthalmology & Visual Science2016-07-1284 citations

Multimodal assessment of choroideremia patients defines pre-treatment characteristics.

2015-03-0731 citations

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

2014-01-16597 citations